Background Prostate cancer (PCa) is the most common male malignancy in the western world. Many men (40%) are diagnosed with localised low or intermediate-risk PCa, which is suitable for active ...
Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...
Genitourinary (GU) cancers, including prostate, bladder, renal and testicular malignancies, represent a heterogeneous group of diseases with varying ...
A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...
Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications ...
Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select® all from the same blood-draw Together, the new applications reinforce Northstar's commitment to ...
Prostate cancer burden in 2026 is high, with disproportionate incidence and mortality in Black men and major survival decrements in distant-stage disease, supporting equitable, stage-shifting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results